EGF vs Matrixyl

Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization, and stimulates collagen and hyaluronic acid production.

Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR) to stimulate cell proliferation, migration, and differentiation in epithelial and mesenchymal cells; it plays a fundamental role in wound healing, skin regeneration, and tissue repair by promoting keratinocyte and fibroblast activation through tyrosine kinase-mediated downstream signaling. EGF activates EGFR tyrosine kinase to initiate PI3K/Akt and MAPK/ERK proliferative signaling cascades; in wound contexts, topically applied recombinant EGF accelerates epithelialization and granulation tissue formation, and injectable EGF has been evaluated for wound bed preparation in diabetic and chronic wounds. Clinical trials of recombinant human EGF for wound healing — including a PubMed-indexed human clinical trial in diabetic foot ulcers — have demonstrated improvements in wound closure and tissue regeneration; recombinant EGF preparations are approved in some countries (Cuba, South Korea) for diabetic wound healing under prescription conditions. Topically applied EGF has no FDA approval in the United States for wound healing or cosmetic applications; recombinant EGF-based wound therapeutics are available internationally under national regulatory approvals outside the US, and EGF is widely incorporated into cosmetic formulations at concentrations where receptor activation and clinical benefit have not been independently validated.

Palmitoylated pentapeptide fragment of collagen I; binds TGF-β receptors on fibroblasts; upregulates collagen I, III, and fibronectin; procollagen production via MAPK pathway

Matrixyl (palmitoyl pentapeptide-4; Pal-KTTKS; Pal-Lys-Thr-Thr-Lys-Ser) is a fatty acid-conjugated synthetic pentapeptide derived from the pro-collagen I sequence, developed by Sederma as a cosmetic active ingredient to stimulate dermal matrix synthesis by mimicking matrikine signaling — the natural cellular response that occurs when collagen fragments are generated during extracellular matrix turnover, triggering fibroblast activity to replenish structural proteins. The palmitoyl chain enhances penetration through the lipid-rich stratum corneum; once absorbed, the KTTKS matrikine sequence is proposed to stimulate fibroblast production of collagen I, collagen IV, fibronectin, and hyaluronic acid through TGF-beta-independent matrix signaling, potentially improving skin structural integrity without hormonal or receptor-agonist activity. A published split-face human clinical study using profilometry examined topical Pal-KTTKS in photoaged facial skin and reported measurable reductions in facial line depth and skin roughness parameters; this is the primary indexed human evidence for matrixyl, though the study was industry-affiliated and effects modest by pharmaceutical standards. Matrixyl is classified as a cosmetic ingredient, not a drug, and has no FDA drug approval; it requires no prescription and is widely incorporated into commercial anti-aging formulations; independent replication of the published findings is limited, and the compound should be understood as a cosmetically active ingredient rather than a clinically validated therapeutic agent. Matrixyl 3000: the second-generation formulation Matrixyl 3000 is the trade name for a second Sederma formulation that combines the original Matrixyl peptide (palmitoyl pentapeptide-4 / Pal-KTTKS) with palmitoyl tetrapeptide-7 (Pal-GQPR). The two peptides are proposed to address different aspects of skin matrix degradation: Matrixyl (Pal-KTTKS) primarily stimulates new collagen synthesis via the TGF-β pathway; palmitoyl tetrapeptide-7 is proposed to inhibit the overproduction of IL-6, an inflammatory interleukin associated with accelerated collagen breakdown and glycosylation-related aging. Together the combination targets both the anabolic (synthesis) and catabolic (degradation) sides of collagen turnover. The 2009 Levin and Maibach review and independent cosmetic studies report wrinkle depth reductions in the range of 15–25% over 8–12 weeks of daily application — results cited widely in the cosmetic industry as benchmark data for peptide-based anti-aging actives. Matrixyl 3000 appears as an ingredient in a large number of commercial anti-aging serums and moisturizers, typically at concentrations of 4–8% of the combined peptide solution (the actual peptide content within the proprietary Sederma dilution is lower). For consumers comparing the original Matrixyl with Matrixyl 3000, the latter is generally considered the stronger formulation for photoaged skin with existing collagen deficit, while the original Matrixyl is sufficient for preventative use.